重组人血管内皮抑制素注射液联合顺铂注射液治疗恶性胸腔积液的临床研究  

Clinical trial of recombinant human endostatin injection combined with cisplatin injection in the treatment of malignant pleural effusion

作　　者：宋文灿[1] 鲍瑜[1] 钱江 朱立建 操思源 陶正平 SONG Wen - can, BAO Yu, QIAN jiang, ZHU Li -jian, CAO Si - yuan, TAO Zheng - ping(Department of Oncology, Chizhou People＇ s Hospital, Chizhou 247000, Anhui Province, Chin)

机构地区：[1]池州市人民医院肿瘤科,安徽池州247000

出　　处：《中国临床药理学杂志》2018年第7期802-804,共3页The Chinese Journal of Clinical Pharmacology

基　　金：中华国际医学交流基金会资助项目(Z-2014-06-16347;Z-2014-06-16348)

摘　　要：目的观察重组人血管内皮抑制素注射液联合顺铂注射液治疗恶性胸腔积液的临床疗效及安全性。方法将60例恶性胸腔积液患者随机分为对照组和试验组,每组30例。对照组予以顺铂每次60 mg,每周2次,胸腔灌注;试验组在对照组治疗的基础上,予以重组人血管内皮抑制素每次45 mg,每周2次,胸腔灌注。2组患者均治疗3个月,每月顺铂剂量不超过120 mg,胸水消失停止治疗。比较2组患者的临床疗效和药物不良反应的发生情况。结果治疗后,试验组和对照组的疾病控制率分别为80.00%(24例/30例)和60.00%(18例/30例),差异有统计学意义(P<0.05)。2组患者的药物不良反应以胃肠道反应、发热、乏力、白细胞减少、血小板减少和肝肾功能损害为主,且其发生率比较,差异均无统计学意义(均P>0.05)。结论重组人血管内皮抑制素注射液联合顺铂注射液治疗恶性胸腔积液的临床疗效确切,且不增加药物不良反应发生率。Objective To observe the clinical efficacy and safety of recombinant human endostatin injection combined with cisplatin injection in the treatment of malignant pleural effusion. Methods Sixty patients with malignant pleural effusion were randomly divided into control and treatment group with 30 cases per group. Control group was given 60 mg per time, twice a week, thoracic perfusion. Treatment group was given recombinant human endostatin 45 mg per time, twice a week, thoracic perfusion, on the basis of control group. Two groups were treated for 3 months. The dose of cisplatin is not more than 120 mg per month, and the disappearance of hydrothorax is stopped. The clinical efficacy and adverse drug reactions were compared between two groups. Results After treatment, the disease control rates of treatment and control groups were 80. 00% （24 cases / 30 cases） and 60. 00% （18 cases / 30 cases） with significant difference （ P 〈 0. 05 ）. The adverse drug reactions in two groups were gastrointestinal reactions, fever, fatigue, leukopenia, throm- bocytopenia, liver and kidney function damage, and their incidences of adverse drug reactions had no statistically significant difference （all P 〉 0.05 ）. Conclusion Recombinant human endostatin injection com- bined with cisplatin injection has a definitive clinical efficacy in the treat- ment of malignant pleural effusion, without increasing the incidence ofadverse drug reactions.

关 键 词：重组人血管内皮抑制素注射液 顺铂注射液 恶性胸腔积液 安全性 

分 类 号：R979.1[医药卫生—药品]